Sunday, April 1
The Cancer Biology Revolution: From Concept to Clinic
Chairperson: Benjamin G. Neel, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada
Emerging landscape of the tumor genome
Elaine Mardis, Washington University School of Medicine, St. Louis, MO
The genetic basis for cancer therapeutics
William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA
Mobilizing the immune system to treat cancer: New insights and opportunities
James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY
Human papillomavirus in the etiology and prevention of genital cancers
Nubia Muñoz, Consultant, Lyon, France
Molecular mechanisms of epigenetic inheritance
Danny F. Reinberg, NYU Langone Medical Center, New York, NY
|
Monday, April 2
Tumor Heterogeneity: Challenges and Therapeutic Opportunities
Chairperson: Lisa M. Coussens, Knight Cancer Institute Oregon Health & Science University, Portland, OR
Normalizing tumor microenvironment to treat cancer
Rakesh K. Jain, Massachusetts General Hospital, Boston, MA
Reprogramming immune microenvironments in solid tumors and therapy
Lisa M. Coussens
Stem cells in self-renewal and cancer
Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands
Genomic mapping of cancer origins
Richard J. Gilbertson, St. Jude Children’s Research Hospital, Memphis, TN
|
Tuesday, April 3
Immune Therapies: The Future Is Now
Chairperson: Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX
Targeted blockade of immune checkpoints in cancer therapy
Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
Chimeric antigen receptor T-cells for leukemia and more?
Carl H. June, Abramson Family Cancer Center Research Institute, University of Pennsylvania, Philadelphia, PA
Current status of recombinant pox-viral vaccines
James L. Gulley, National Cancer Institute, Bethesda, MD
T-cell therapy
Patrick Hwu
|
Wednesday, April 4
Pathway-Targeted Therapeutics: Coming of Age
Chairperson: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY
Overcoming cancer drug resistance
Charles L. Sawyers
Ras and Raf signaling: From biology to therapeutics
Richard M. Marais, Institute of Cancer Research, London, United Kingdom
ALK in non-small cell lung cancer: Understanding sensitivity and resistance to ALK inhibition
Alice T. Shaw, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Cell signaling by receptor tyrosine kinases: From basic principles to cancer therapy
Joseph Schlessinger, Yale University School of Medicine, New Haven, CT
|